X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5) 5
index medicus (4) 4
oncology (4) 4
cancer (3) 3
chemotherapy (3) 3
adult (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - pharmacokinetics (2) 2
bioavailability (2) 2
carcinoma (2) 2
clinical medicine (2) 2
enzymes (2) 2
female (2) 2
hematology, oncology and palliative medicine (2) 2
metabolism (2) 2
middle aged (2) 2
neoplasms - drug therapy (2) 2
patients (2) 2
phase-i (2) 2
phenotype (2) 2
protein kinase inhibitors - pharmacokinetics (2) 2
treatment outcome (2) 2
tumors (2) 2
acids (1) 1
adjuvant tamoxifen (1) 1
administration, intravenous (1) 1
administration, oral (1) 1
advanced solid tumors (1) 1
aged (1) 1
allele frequencies (1) 1
analysis (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - metabolism (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, hormonal - therapeutic use (1) 1
antineoplastic agents, hormonal/therapeutic use (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
association (1) 1
biological availability (1) 1
brca1 protein - genetics (1) 1
brca2 protein - genetics (1) 1
breast neoplasms - drug therapy (1) 1
breast neoplasms - enzymology (1) 1
breast neoplasms - pathology (1) 1
breast neoplasms/drug therapy/enzymology/pathology (1) 1
cancer therapies (1) 1
carboplatin - administration & dosage (1) 1
care and treatment (1) 1
chronic myeloid-leukemia (1) 1
cisplatin (1) 1
clearance (1) 1
clinical study (1) 1
clinical-implications (1) 1
cohort studies (1) 1
combination (1) 1
cyclin-dependent kinases (1) 1
cyp (1) 1
cyp2d6 (1) 1
cyp3a4 inhibition (1) 1
cytochrome p-450 (1) 1
cytochrome p-450 cyp2d6 - genetics (1) 1
cytochrome p-450 cyp2d6 - metabolism (1) 1
cytochrome p-450 cyp2d6 inhibitors (1) 1
cytochrome p-450 cyp2d6/antagonists & inhibitors/genetics/metabolism (1) 1
cytochrome p-450 enzyme system - genetics (1) 1
cytochrome p450 (1) 1
cytochrome-p450 (1) 1
deoxyribonucleic acid--dna (1) 1
digestive system (1) 1
disease-free survival (1) 1
diseases (1) 1
docetaxel clearance (1) 1
dosage and administration (1) 1
dose-response relationship (1) 1
dose-response relationship, drug (1) 1
drug administration schedule (1) 1
drug approval (1) 1
drug dosages (1) 1
drug interactions (1) 1
drug therapy (1) 1
enzyme inhibitors - administration & dosage (1) 1
enzyme inhibitors - adverse effects (1) 1
enzyme inhibitors - therapeutic use (1) 1
enzyme inhibitors/therapeutic use (1) 1
erythromycin breath test (1) 1
estrogen-receptor modulators (1) 1
exposure decreases (1) 1
feasibility studies (1) 1
gene mutations (1) 1
genotype (1) 1
genotyping (1) 1
grapefruit juice (1) 1
healthy-subjects (1) 1
hospitals (1) 1
hot flashes (1) 1
human cyp2c subfamily (1) 1
human liver-microsomes (1) 1
imatinib mesylate gleevec (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.